Molbio Diagnostics Ltd
Incorporated in October 2000, Molbio Diagnostics Limited is a global point-
of-care (POC) molecular diagnostics
company engaged in the research,
development, manufacturing, and commercialization of rapid diagnostic
solutions.[1]
- Market Cap ₹ 12,659 Cr.
- Current Price ₹ 1,098
- High / Low ₹ 1,177 / 926
- Stock P/E 75.7
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 18.5 %
- ROE 15.6 %
- Face Value ₹ 1.00
Pros
- Company's working capital requirements have reduced from 148 days to 116 days
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Equipment & Supplies Medical Equipment & Supplies
Part of BSE IPO
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| 837 | 1,020 | 1,446 | |
| 602 | 760 | 1,126 | |
| Operating Profit | 234 | 260 | 320 |
| OPM % | 28% | 26% | 22% |
| -49 | -4 | 9 | |
| Interest | 14 | 18 | 33 |
| Depreciation | 41 | 45 | 64 |
| Profit before tax | 130 | 194 | 231 |
| Tax % | 36% | 29% | 29% |
| 84 | 139 | 164 | |
| EPS in Rs | 452.37 | 64.34 | 14.77 |
| Dividend Payout % | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 42% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 10% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 16% |
| Last Year: | 16% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 2 | 2 | 11 |
| Reserves | 821 | 966 | 1,158 |
| 184 | 147 | 450 | |
| 211 | 346 | 496 | |
| Total Liabilities | 1,218 | 1,461 | 2,115 |
| 289 | 290 | 536 | |
| CWIP | 2 | 27 | 11 |
| Investments | 6 | 46 | 6 |
| 921 | 1,099 | 1,562 | |
| Total Assets | 1,218 | 1,461 | 2,115 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| 10 | 287 | 50 | |
| -45 | -123 | -54 | |
| -32 | -26 | 276 | |
| Net Cash Flow | -67 | 138 | 273 |
| Free Cash Flow | -7 | 232 | 1 |
| CFO/OP | 23% | 141% | 38% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Debtor Days | 186 | 97 | 103 |
| Inventory Days | 338 | 384 | 285 |
| Days Payable | 101 | 203 | 126 |
| Cash Conversion Cycle | 423 | 278 | 261 |
| Working Capital Days | 200 | 128 | 116 |
| ROCE % | 21% | 18% |
Documents
Announcements
Annual reports
No data available.